Aranda, E., Viéitez, J. M., Gómez-España, A., Gil Calle, S., Salud-Salvia, A., Graña, B., . . . Díaz-Rubio, E. (2020). FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial. ESMO Open.
Citação norma ChicagoAranda, Enrique, et al. "FOLFOXIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab for Patients With Metastatic Colorectal Cancer and ≥3 Circulating Tumour Cells: The Randomised Phase III VISNÚ-1 Trial." ESMO Open 2020.
Citação norma MLAAranda, Enrique, et al. "FOLFOXIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab for Patients With Metastatic Colorectal Cancer and ≥3 Circulating Tumour Cells: The Randomised Phase III VISNÚ-1 Trial." ESMO Open 2020.